Icotinib and Endostar [20-23] are primary research drugs in China, and studies have shown that they are as effective as the other first-generation drugs EGFR-TKI and bevacizumab in patients with lung cancer in China [24,25]. This evidence concerns the gene EGFR and lung cancer.